Christopher Larson

Title: Innovations by Christopher Larson in Cancer Treatment

Introduction

Christopher Larson is a prominent inventor based in San Diego, CA, known for his significant contributions to the field of cancer treatment. With a total of 13 patents to his name, Larson has focused on developing innovative solutions that enhance the effectiveness of cancer therapies.

Latest Patents

One of Larson's latest patents involves personalized cancer vaccines. This invention provides a recombinant adenoviral vector that includes a modified transcription regulatory sequence, making it transcriptionally active in cancer cells while being attenuated in normal cells. Additionally, it contains a transgene encoding cancer antigens specific to a subject. This recombinant oncolytic adenoviral vector is designed to stimulate a heightened immune response against cancer antigens, offering a promising method for treating cancer. Another notable patent involves A549 host cells that utilize a recombinant oncolytic adenovirus with a modified E1A cancer-specific promoter, showcasing his innovative approach to viral therapy.

Career Highlights

Throughout his career, Christopher Larson has worked with several companies, including Epicentrx, Inc. and Itherx Pharmaceuticals Inc. His work has been instrumental in advancing cancer treatment technologies, and his patents reflect a deep understanding of both virology and immunology.

Collaborations

Larson has collaborated with notable professionals in the field, including Tony R Reid and Bryan T Oronsky. These partnerships have contributed to the development of his groundbreaking inventions.

Conclusion

Christopher Larson's innovative work in cancer treatment through personalized vaccines and recombinant viral vectors positions him as a key figure in the fight against cancer. His contributions continue to pave the way for new therapeutic strategies that could significantly improve patient outcomes.